COMPANY
VISION
Company Profile and Leaders
Drug-PIN SA
Was founded in 2018 by a group of scientists pioneering the field of personalised medicine together with leading European business partners.
Principle Office
DRUG-PIN SA
Via Francesco Somaini, 10 - 6900 Lugano, Switzerland
Company Registry #
CHE-482.058.077
Email: info@drug-pin.com
Scientific Advisory Board
Dr. Robert Preissner, Ph.D.
Is a leading researcher and scientist in the fields of Structural Bioinformatics, Data Science, Pharmacogenomics and Pharmacokinetics with more than 130 publications. Before his cutting-edge work with Drug-PIN, he served as the Head of Science-IT at Charité University in Berlin, Germany, as well as other roles including Coordinator of the Clinical Research Unit and Department Head of the Institute of Physiology. Outside of the university he contributes to a number of organisations including the Clinical Research Unit at ECRC and BIH, the German Consortium for Transnational Cancer Research (DKTK) and the National Consortium for Systems Immunology. Previously he led a number of Departments in Molecular Biology, Bioinformatics and Allergy & Immunology in Germany as well as San Diego, California (UCSD, La Jolla Institute).
A number of recent publications that have led to the development of the Drug-PIN solution include:
The target landscape of clinical kinase drugs - Science (IF: 37.205), 358(6367), 2018.
Pain prescription: an analysis of 500,000 discharge summaries. Curr. Drug Abuse Rev. 2018 (in press)
CardioScape mapping the cardiovascular funding landscape in Europe. Eur Heart J. (IF: 20.212) 10.1093/eurheartj/ehx106, 2018.
Drugs as habitable planets in the space of dark chemical matter. Drug Discov Today. (IF: 6.848) 23(3): 481-486, 2018.
SuperDRUG2: a one stop resource for approved/marketed drugs. Nucleic Acids Res. (IF: 11.561) 46: D1137-D1143, 2017.
WITHDRAWN: a resource for withdrawn and discontinued drugs. Nucleic Acids Res. (IF: 11.561) 44: D1080-6, 2016.
His profile can also be found at: http://bioinformatics.charite.de
Dr. Robert Preissner, Ph.D. is a leading researcher and scientist in the fields of Structural Bioinformatics, Data Science, Pharmacogenomics and Pharmacokinetics with more
Read More
Dr. Maurizio Simmaco, MD
In this context, he developed and described original methodologies based on the use of HPLC and LC-MS / MS technologies.
He discovered and described the structure, function, mechanism of action and regulation of natural peptides provided with antimicrobial activity, among which the Temporine and the Esculentina, object of specific patents.
He is an expert in functional biochemistry applied to the evaluation of the individual capability to metabolize correctly drugs and xenobiotics.
He is member of the board of European Society Pharmacogenomics and Personalized Therapy (ESPT) and he has published more than 155 papers.
He also contributes to a number of organisations that carry out health initiatives for Ethiopia and Sudan.
His publications can be viewed here:
http://www.ncbi.nlm.nih.gov/pubmed?term=simmaco
Is a leading researcher and professor of Biochemistry and Molecular Biology, specialising in Clinical Analysis Laboratory, at Sapienza University in Rome, Italy, where he has developed his scientific career in the "Alessandro Rossi Fanelli" Department of Biochemistry
Read More
Dr. Luca Marchetti, MD
Dr. Luca Marchetti, MD is an Oncologist at San Pietro FBF Hospital and a Medical Oncologist consultant at UPMC San Pietro FBF in the Advanced Radiotherapy Center lUPMC at the University of Pittsburgh Medical Center.
He is a Medical Oncologist at Paideia and Mater Dei.
In 2016, he received a doctorate degree in Molecular Medicine after completing his Postgraduate course in Medical Oncology and received his medical degree at the School of Medicine, Università “La Sapienza”, Rome, Italy.
Dr. Luca Marchetti, MD is an Oncologist at San Pietro FBF Hospital and a Medical Oncologist consultant at UPMC San Pietro FBF in the Advanced Radiotherapy Center lUPMC at the University of Pittsburgh Medical Center.
Read More
Professor Paolo Marchetti, M.D., Ph.D.
He is founder and President of the Italian Society of Personalized Medicine (S.I.Me.P.), founder and President of the Italian Foundation of Personalized Medicine and is member of many national and international cancer societies, including AIOM, ESMO and ASCO. His principle areas of expertise include: Alterations of hormone receptor status in hormone related tumours and their clinical implications on prognosis and therapy; chemoprevention of breast cancer; familial/hereditary breast cancer and BRCA1/2 mutations; clinical implications of the inactivation of tumor suppressor genes in solid tumors; innovative molecular scanning techniques for the detection of gene mutations; treatment of breast cancer, melanoma, lung, colorectal and gynecological cancers; supportive and palliative care in cancer patients.
Prof. Marchetti invented the electronic-dolometer, an electronic device to measure pain perception and quality of life in cancer patients. He also coordinates a supportive care research group that has published several papers and has produced clinical recommendations on symptom treatment in the framework of simultaneous care, and coordinates several research groups in the area of immune-oncology and network medicine.
Professor Paolo Marchetti, M.D., Ph.D. is Professor and Head of Medical Oncology at the School of Medicine and Psychology at Sapienza University in Rome, Italy, and directs the postgraduate
Read More
Prof. Sir Munir Pirmohamed, MB ChB
Professor Sir Munir Pirmohamed qualified in Medicine in 1985, undertook a PhD in Pharmacology in 1993, and was appointed Consultant Physician at the Royal Liverpool University Hospital in 1996. He was awarded a Personal Chair in Clinical Pharmacology at the University of Liverpool in 2001, and in 2007, was appointed to the NHS Chair of Pharmacogenetics. He was awarded a Knights Bachelor in the Queen's Birthday Honours list in 2015.
He is Associate Executive Pro-Vice Chancellor for Clinical Research for the Faculty of Health and Life Sciences; Director of the MRC Centre for Drug Safety Sciences in Liverpool; Director of the Wolfson Centre for Personalised Medicine; Executive Director for Liverpool Health Partners; a Member of the Commission on Human Medicines and Chair of its Pharmacovigilance Expert Advisory Group. He is also an inaugral NIHR Senior Investigator, and a Fellow of the Academy of Medical Sciences in the UK.
His main area of research is in pharmacogenetics and drug safety. Adverse reactions to drugs are a major cause of illness in the population - the research aims to maximise the benefits of drugs and minimize their harms. This is being achieved through the use of different strategies, ranging from improvements in prescribing, to the development of genetic and other tests for predicting and monitoring individual susceptibility to toxicity.
Current Appointments: David Weatherall Chair of Medicine, NHS Chair of Pharmacogenetics, Honorary Consultant Physician at the Royal Liverpool University Hospital, Director of the MRC Drug Safety Science, Director of the Wolfson Centre for Personalised Medicine
Peter Daniel, M.D., Ph.D.
Peter Daniel, M.D., Ph.D. is Professor and Head of Clinical and Molecular Medicine at the University Medical Center Charité, Humboldt University of Berlin, and Max Delbrück Centre for Molecular Medicine, Berlin, Germany. His experience includes Postdoctoral studies at the Institute for Immunogenetics at the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ) in Heidelberg, Germany.
In 2004 he was appointed to his current position at the University Medical Centre “Charité” of the Humboldt University of Berlin. He is a peer reviewer for key journals in oncology and life sciences and since 1996 he has served as scientific expert to the European Commission in numerous calls. Since 2007 he has served as an ethics expert to the European Commission and helped to establish and shape the ethics screening and assessment procedures for numerous calls including:
  • European Commission DG Health
  • European Commission Ethics sector
  • European Research Council (ERC)
  • EASME (Executive Agency for Small and Medium-sized Enterprises)
  • Innovative Medicines Initiatives (IMI) co-funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Marie Curie programme
Peter Daniel, M.D., Ph.D. is Professor and Head of Clinical and Molecular Medicine at the University Medical Center Charité, Humboldt University of Berlin, and Max Delbrück Centre for Molecular Medicine, Berlin,
Read More
Business & Marketing Leadership
Mr. Renato Della Valle
Mr. Renato Della Valle is a businessman, real estate entrepreneur and investor with extensive experience in growing businesses and a particular interest in innovation. He started his career working for the newspaper ‘il Giorno’ in Milan in 1961 responsible for special services and new initiatives. In the first 6 months he convinced the merchants of Via Paolo Sarpi to advertise as a street and not as individual shops which resulted in great success for all.
In 1963 he started working for Gabetti, Italy’s leading real estate firm, shortly after taking the position of Director of Sales at Castello Real Estate. In just 3 years he increased company revenues from €3 billion to €30 billion annually.
In 1969 Mr. Della Valle founded his own real estate company - Della Valle Immobiliare - with the slogan “Where do you go if you don’t have a house?” based in Milan. Additionally from 1975-78 he became CEO of the fashion brand Giorgio Armani and a 25% shareholder in the company. He began exploring new ventures thereafter such as the founding the company Clexidra with a new model for consumption-based car insurance based on distance travelled.
In 1985 Mr. Della Valle founded the company SIB (Servizi Immobiliari Banche) which provided banks with real estate services. It became the first Italian company to deal with real estate related non performing loans in the banking system, with the participation of all Italian banks through ABI (Associazione Bancaria Italiana).
Then he founded the company Diffusion Phone and he was the first to develop a colored mobile phone without an antenna for the German company Hagenuk and signing an agreement with Ferrari Auto to make colored phones (red, yellow, black, metallic) with the Ferrari logo.
More recently in 2005 he entered the pharmaceutical industry by founding the pharma company NMTECH in London. In 2017 he started a new venture in personalised medicine and founded the company Drug-PIN in 2018. Today he is the CEO and one of the primary investors of Drug-PIN
Mr. Renato Della Valle is a businessman, real estate entrepreneur and investor with extensive experience in growing businesses and a particular interest in innovation. He started his career working for
Read More
Mr. Marco Della Valle
Is a businessman, entrepreneur and real estate investor who has been the founding member of more than 8 real estate companies and has developed hundreds of residential, commercial and industrial properties in the regions of Milan, Modena and Bologna, Italy.
He is a founding member of the photovoltaic systems company, Seifin S.P.A., the parent company of Destiny SRL that manages photovoltaic systems with annual power generation totalling 12 megawatts.
He is also a shareholder of a real estate company, which holds real estate properties in Milan.
Mr. Della Valle also collaborates with Urban Vision S.P.A, in order to promote and implement large advertising systems. A shareholder for a company specialising in the development of high end shopping centres, which operate in Europe, Romania and Russia.
Mr. Della Valle holds the role of Chairman of the Board of Directors.
Is a businessman, entrepreneur and real estate investor who has been the founding member of more than 8 real estate companies and has developed hundreds of residential, commercial and industrial properties
Read More
Team
Datawizard
Management, Design & Front-End Development
A developer of mobile and web digital health applications covering the entire production stack in a single, integrated solution, managing big data using a hybrid technology approach with Semantic Search Engine, NLP, Machine Learning, Information Retrieval and Ontology-based techniques. Known for strong UX/UI design and market expertise in e-health and pharma, their most well-known platform is Pharmawizard - a solution for managing daily health through user-friendly services.
Camelot Biomedical Systems
Back-End Development
A team of Machine Learning Specialists, Software Architects and Innovation Experts who have worked in the best artificial intelligence laboratories in the world. Developed innovative tools for Carrefour Italia employees to manage processes ranging from energy consumption forecasting, to monitoring rack loading and cleaning operations. Camelot is supporting the Lombardia Region in the design and implementation of innovative projects that, by leveraging technologies such as artificial intelligence and block chain, are aimed at transforming the role played by Region in areas as diverse as innovation policies, environmental protection, professional education, healthcare.
BACK
Dr. Robert Preissner, Ph.D.
Is a leading researcher and scientist in the fields of Structural Bioinformatics, Data Science, Pharmacogenomics and Pharmacokinetics with more than 130 publications. Before his cutting-edge work with Drug-PIN, he served as the Head of Science-IT at Charité University in Berlin, Germany, as well as other roles including Coordinator of the Clinical Research Unit and Department Head of the Institute of Physiology. Outside of the university he contributes to a number of organisations including the Clinical Research Unit at ECRC and BIH, the German Consortium for Transnational Cancer Research (DKTK) and the National Consortium for Systems Immunology. Previously he led a number of Departments in Molecular Biology, Bioinformatics and Allergy & Immunology in Germany as well as San Diego, California (UCSD, La Jolla Institute).

A number of recent publications that have led to the development of the Drug-PIN solution include:

The target landscape of clinical kinase drugs - Science (IF: 37.205), 358(6367), 2018.

Pain prescription: an analysis of 500,000 discharge summaries. Curr. Drug Abuse Rev. 2018 (in press)

CardioScape mapping the cardiovascular funding landscape in Europe. Eur Heart J. (IF: 20.212) 10.1093/eurheartj/ehx106, 2018. 

Drugs as habitable planets in the space of dark chemical matter. Drug Discov Today. (IF: 6.848) 23(3): 481-486, 2018.

SuperDRUG2: a one stop resource for approved/marketed drugs. Nucleic Acids Res. (IF: 11.561) 46: D1137-D1143, 2017.

WITHDRAWN: a resource for withdrawn and discontinued drugs. Nucleic Acids Res. (IF: 11.561) 44: D1080-6, 2016.

His profile can also be found at: http://bioinformatics.charite.de

BACK
Dr. Maurizio Simmaco, MD
Is a leading researcher and professor of Biochemistry and Molecular Biology, specialising in Clinical Analysis Laboratory, at Sapienza University in Rome, Italy, where he has developed his scientific career in the "Alessandro Rossi Fanelli" Department of Biochemistry by studying the structure and function of proteins and peptides involved in the body's defence mechanisms against free oxygen radicals and infectious agents.
In this context, he developed and described original methodologies based on the use of HPLC and LC-MS / MS technologies.
He discovered and described the structure, function, mechanism of action and regulation of natural peptides provided with antimicrobial activity, among which the Temporine and the Esculentina, object of specific patents.
He is an expert in functional biochemistry applied to the evaluation of the individual capability to metabolize correctly drugs and xenobiotics.
He is member of the board of European Society Pharmacogenomics and Personalized Therapy (ESPT) and he has published more than 155 papers.
He also contributes to a number of organisations that carry out health initiatives for Ethiopia and Sudan.
His publications can be viewed here: http://www.ncbi.nlm.nih.gov/pubmed?term=simmaco
BACK
Prof. Sir Munir Pirmohamed, MB ChB (with Honours), PhD, FRCP, FRCP (Edin), FFPM (Hon), FRSB, FBPhS, FMedSc
Professor Sir Munir Pirmohamed qualified in Medicine in 1985, undertook a PhD in Pharmacology in 1993, and was appointed Consultant Physician at the Royal Liverpool University Hospital in 1996. He was awarded a Personal Chair in Clinical Pharmacology at the University of Liverpool in 2001, and in 2007, was appointed to the NHS Chair of Pharmacogenetics. He was awarded a Knights Bachelor in the Queen's Birthday Honours list in 2015.
He is Associate Executive Pro-Vice Chancellor for Clinical Research for the Faculty of Health and Life Sciences; Director of the MRC Centre for Drug Safety Sciences in Liverpool; Director of the Wolfson Centre for Personalised Medicine; Executive Director for Liverpool Health Partners; a Member of the Commission on Human Medicines and Chair of its Pharmacovigilance Expert Advisory Group. He is also an inaugral NIHR Senior Investigator, and a Fellow of the Academy of Medical Sciences in the UK.
His main area of research is in pharmacogenetics and drug safety. Adverse reactions to drugs are a major cause of illness in the population - the research aims to maximise the benefits of drugs and minimize their harms. This is being achieved through the use of different strategies, ranging from improvements in prescribing, to the development of genetic and other tests for predicting and monitoring individual susceptibility to toxicity.
BACK
Dr. Luca Marchetti, MD
Dr. Luca Marchetti, MD is an Oncologist at San Pietro FBF Hospital and a Medical Oncologist consultant at UPMC San Pietro FBF in the Advanced Radiotherapy Center lUPMC at the University of Pittsburgh Medical Center.

He is a Medical Oncologist at Paideia and Mater Dei.

In 2016, he received a doctorate degree in Molecular Medicine after completing his Postgraduate course in Medical Oncology and received his medical degree at the School of Medicine, Università “La Sapienza”, Rome, Italy.
BACK
Professor Paolo Marchetti, M.D., Ph.D.
He is founder and President of the Italian Society of Personalized Medicine (S.I.Me.P.), founder and President of the Italian Foundation of Personalized Medicine and is member of many national and international cancer societies, including AIOM, ESMO and ASCO. His principle areas of expertise include: Alterations of hormone receptor status in hormone related tumours and their clinical implications on prognosis and therapy; chemoprevention of breast cancer; familial/hereditary breast cancer and BRCA1/2 mutations; clinical implications of the inactivation of tumor suppressor genes in solid tumors; innovative molecular scanning techniques for the detection of gene mutations; treatment of breast cancer, melanoma, lung, colorectal and gynecological cancers; supportive and palliative care in cancer patients.

Prof. Marchetti invented the electronic-dolometer, an electronic device to measure pain perception and quality of life in cancer patients. He also coordinates a supportive care research group that has published several papers and has produced clinical recommendations on symptom treatment in the framework of simultaneous care, and coordinates several research groups in the area of immune-oncology and network medicine.
BACK
Peter Daniel, M.D., Ph.D.
Peter Daniel, M.D., Ph.D. is Professor and Head of Clinical and Molecular Medicine at the University Medical Center Charité, Humboldt University of Berlin, and Max Delbrück Centre for Molecular Medicine, Berlin, Germany. His experience includes Postdoctoral studies at the Institute for Immunogenetics at the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ) in Heidelberg, Germany.

In 2004 he was appointed to his current position at the University Medical Centre “Charité” of the Humboldt University of Berlin. He is a peer reviewer for key journals in oncology and life sciences and since 1996 he has served as scientific expert to the European Commission in numerous calls. Since 2007 he has served as an ethics expert to the European Commission and helped to establish and shape the ethics screening and assessment procedures for numerous calls including:

  • European Commission DG Health
  • European Commission Ethics sector
  • European Research Council (ERC)
  • EASME (Executive Agency for Small and Medium-sized Enterprises)
  • Innovative Medicines Initiatives (IMI) co-funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Marie Curie programme
BACK
Mr. Renato Della Valle
Mr. Renato Della Valle is a businessman, real estate entrepreneur and investor with extensive experience in growing businesses and a particular interest in innovation. He started his career working for the newspaper ‘il Giorno’ in Milan in 1961 responsible for special services and new initiatives. In the first 6 months he convinced the merchants of Via Paolo Sarpi to advertise as a street and not as individual shops which resulted in great success for all.

In 1963 he started working for Gabetti, Italy’s leading real estate firm, shortly after taking the position of Director of Sales at Castello Real Estate. In just 3 years he increased company revenues from €3 billion to €30 billion annually.

In 1969 Mr. Della Valle founded his own real estate company - Della Valle Immobiliare - with the slogan “Where do you go if you don’t have a house?” based in Milan. Additionally from 1975-78 he became CEO of the fashion brand Giorgio Armani and a 25% shareholder in the company. He began exploring new ventures thereafter such as the founding the company Clexidra with a new model for consumption-based car insurance based on distance travelled.

In 1985 Mr. Della Valle founded the company SIB (Servizi Immobiliari Banche) which provided banks with real estate services. It became the first Italian company to deal with real estate related non performing loans in the banking system, with the participation of all Italian banks through ABI (Associazione Bancaria Italiana).

Then he founded the company Diffusion Phone and he was the first to develop a colored mobile phone without an antenna for the German company Hagenuk and signing an agreement with Ferrari Auto to make colored phones (red, yellow, black, metallic) with the Ferrari logo.

More recently in 2005 he entered the pharmaceutical industry by founding the pharma company NMTECH in London. In 2017 he started a new venture in personalised medicine and founded the company Drug-PIN in 2018. Today he is the CEO and one of the primary investors of Drug-PIN.
BACK
Mr. Marco Della Valle
Is a businessman, entrepreneur and real estate investor who has been the founding member of more than 8 real estate companies and has developed hundreds of residential, commercial and industrial properties in the regions of Milan, Modena and Bologna, Italy.

He is a founding member of the photovoltaic systems company, Seifin S.P.A., the parent company of Destiny SRL that manages photovoltaic systems with annual power generation totalling 12 megawatts.

He is also a shareholder of a real estate company, which holds real estate properties in Milan.

Mr. Della Valle also collaborates with Urban Vision S.P.A, in order to promote and implement large advertising systems. A shareholder for a company specialising in the development of high end shopping centres, which operate in Europe, Romania and Russia.

Mr. Della Valle holds the role of Chairman of the Board of Directors.